Jing-Bo Sun

Dr. Jing-Bo Sun


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2023 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
WLWei-Jie Lv
Wei-Jie Lv
JHJie-Yi Huang
Jie-Yi Huang
JLJin Lin
Jin Lin
YMYi-Mu Ma
Yi-Mu Ma
SHShi-Qi He
Shi-Qi He
SGShining Guo
Shining Guo
Phytosterols (PS) have been shown to regulate cholesterol metabolism and alleviate hyperlipidemia (HLP), but the mechanism is still unclear. In this study, we investigated the mechanism by which PS regulates cholesterol metabolism in high-fat diet (HFD) mice. The results showed that PS treatment reduced the accumulation of total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) in the serum of HFD mice, while increasing the serum levels of high-density lipoprotein cholesterol (HDL-C). Compared with HFD mice, PS not only increased the antioxidant activity of the liver but also regulated the mRNA expression levels of enzymes and receptors related to cholesterol metabolism. The hypolipidemic effect of PS was abolished by antibiotic (Abx) intervention and reproduced by fecal transplantation (FMT) intervention. The results of 16S rRNA sequencing analysis showed that PS modulated the gut microbiota of mice. PS reduced the relative abundance of Lactobacillus and other bile salt hydrolase- (BSH-) producing gut microbiota in HFD mice, which are potentially related to cholesterol metabolism. These findings partially explain the mechanisms by which PS regulates cholesterol metabolism. This implies that regulation of the gut microbiota would be a potential target for the treatment of HLP.

16 August 2022 in Frontiers in Nutrition
Verified
Journal Article
Open access
WLWei-Jie Lv
Wei-Jie Lv
JHJie-Yi Huang
Jie-Yi Huang
SLShu-Peng Li
Shu-Peng Li
XGXiao-Pei Gong
Xiao-Pei Gong
JSJing-Bo Sun
Jing-Bo Sun
SGShining Guo
Shining Guo
Atopic dermatitis (AD) is a common chronic allergic skin disease characterized clinically by severe skin lesions and pruritus. Portulaca oleracea L. (PO) is a resourceful plant with homologous properties in medicine and food. In this study, we used two different methods to extract PO, and compared the therapeutic effects of PO aqueous extract (POAE) and PO ultrasound-assisted ethanol extract (POEE) on 2,4-dinitrochlorobenzene (DNCB)-induced AD mice. The results showed that in POAE and POEE, the extraction rates of polysaccharides were 16.95% and 9.85%, while the extraction rates of total flavonoids were 3.15% and 3.25%, respectively. Compared with AD mice, clinical symptoms such as erythema, edema, dryness and ulceration in the back and left ear were alleviated, and pruritus behavior was reduced after POAE and POEE treatments. The thickness of the skin epidermis was thinned, the density of skin nerve fibers labeled with protein gene product 9.5 (PGP9.5) was decreased, and mast cell infiltration was reduced. There was a decrease in blood lymphocytes, eosinophils and basophils, a significant decrease in spleen index and a noticeable decrease in serum immunoglobulin E (Ig E). POEE significantly reduced the concentration of the skin pruritic factor interleukin (Il)-31. POAE and POEE reduced the concentration of skin histamine (His), down-regulated mRNA expression levels of interferon-γ (Ifnγ), tumor necrosis factor-α (Tnf-α), thymic stromal lymphopoietin (Tslp) and Il-4, with an increase of Filaggrin (Flg) and Loricrin (Lor) in skin lesions. These results suggested that POAE and POEE may inhibit atopic response and alleviate the clinical symptoms of AD by inhibiting the expression of immune cells, inflammatory mediators and cytokines. PO may be a potential effective drug for AD-like diseases.

2 May 2024 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
SLShaohua Lyu
Shaohua Lyu
CZClaire Shuiqing Zhang
Claire Shuiqing Zhang
ZMZhenhui Mao
Zhenhui Mao
XGXinfeng Guo
Xinfeng Guo
ZLZhe Li
Zhe Li
QSQiaozhen Su
Qiaozhen Su
Background: Parkinson's disease (PD) is a progressive neurodegenerative condition. Chinese medicine therapies have demonstrated effectiveness for PD in controlled settings. However, the utilization of Chinese medicine therapies for PD in real-world clinical practice and the characteristics of patients seeking these therapies have not been thoroughly summarized.Method: The study retrospectively analyzed initial patient encounters (PEs) with a first-listed diagnosis of PD, based on electronic medical records from Guangdong Provincial Hospital of Chinese Medicine between July 2018 and July 2023.Results: A total of 3,206 PEs, each corresponding to an individual patient, were eligible for analyses. Approximately 60% of patients made initial visits to the Chinese medicine hospital after receiving a PD diagnosis, around 4.59 years after the onset of motor symptoms. Over 75% of the patients visited the Internal Medicine Outpatient Clinic at their initial visits, while a mere 13.85% visited PD Chronic Care Clinic. Rest tremor (61.98%) and bradykinesia (52.34%) are the most commonly reported motor symptoms, followed by rigidity (40.70%). The most commonly recorded non-motor symptoms included constipation (31.88%) and sleep disturbance (25.27%). Integration of Chinese medicine and conventional medicine therapies was the most common treatment method (39.15%), followed by single use of Chinese herbal medicine (27.14%). The most frequently prescribed herbs for PD included Glycyrrhiza uralensis Fisch. (gan cao), Astragalus mongholicus Bunge (huang qi), Atractylodes macrocephala Koidz. (bai zhu), Angelica sinensis (Oliv.) Diels (dang gui), Rehmannia glutinosa (Gaertn.) DC. (di huang), Paeonia lactiflora Pall. (bai shao), Bupleurum chinense DC. (chai hu), Citrus aurantium L. (zhi qiao/zhi shi/chen pi), Panax ginseng C. A. Mey. (ren shen), and Poria cocos (Schw.) Wolf (fu ling). These herbs contribute to formulation of Bu zhong yi qi tang (BZYQT).Conclusion: Patients typically initiated Chinese medical care after the establishment of PD diagnosis, ~4.59 years post-onset of motor symptoms. The prevalent utilization of CHM decoctions and patented Chinese herbal medicine products, underscores its potential in addressing both motor and non-motor symptoms. Despite available evidence, rigorous clinical trials are needed to validate and optimize the integration of CHM, particularly BZYQT, into therapeutic strategies for PD.

1 January 2020 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SLShaohua Lyu
Shaohua Lyu
CZClaire Shuiqing Zhang
Claire Shuiqing Zhang
XGXinfeng Guo
Xinfeng Guo
AZAnthony Lin Zhang
Anthony Lin Zhang
JSJing-Bo Sun
Jing-Bo Sun
XLXiaodong Luo
Xiaodong Luo
Background. The prophylactic effects of Chinese herbal medicine (CHM) for migraine were examined in numerous clinical trials. This review aimed to analyze the effectiveness and safety of CHM as prophylactic treatment of migraine compared to flunarizine. Methods. Nine databases were searched for randomized controlled trials (RCTs) that evaluated effects of CHM for episodic migraine prophylaxis compared to flunarizine, published before March 2019. Results. Thirty‐five RCTs with 2,840 participants met the inclusion criteria, and 31 of them were included in meta‐analyses. The overall meta‐analysis indicated that, when compared to flunarizine, CHM reduced the frequency of migraine attacks at the end of treatment (EoT) (21 studies, mean difference (MD) −1.23, 95% confidence interval (CI) (−1.69, −0.76)) and at the end of follow‐up (EoFU) (five studies, MD −0.96, 95% CI (−1.70, −0.21)). Subgroup analyses based on the treatment duration, follow‐up duration, and the dosage of flunarizine showed that CHM was superior to or comparable with flunarizine in reducing migraine frequency. Similar results were also found for secondary outcomes such as the pain visual analogue scale, migraine duration, responder rate, and acute medication usage. In particular, the studies that used CHM containing herb pairs (Chuan Xiong plus Bai Zhi and Chuan Xiong plus Tian Ma) showed promising results. However, the certainty of this evidence was evaluated as “low” or “very low” using the Grading of Recommendations, Assessment, Development and Evaluations approach. Conclusion. CHM appeared to be comparable with flunarizine in reducing the frequency of episodic migraine attacks in adults at EoT and EoFU and well‐tolerated by participants, regardless of the treatment duration, follow‐up duration, and dosage of flunarizine. Due to the low certainty of the evidence, the suggested promising prophylactic outcomes require higher quality evidence from further rigorous RCTs.

3 March 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WZWen Zhao
Wen Zhao
SYShiyao Yu
Shiyao Yu
YXYan Xu
Yan Xu
HLHuijuan Liao
Huijuan Liao
DCDaiyi Chen
Daiyi Chen
JSJing-Bo Sun
Jing-Bo Sun
Sleep disorders (SDs) are a common issue in the elderly. Epigenetic clocks based on DNA methylation (DNAm) are now considered highly accurate predictors of the aging process and are associated with age-related diseases. This study aimed to investigate the causal relationship between sleep traits and the epigenetic clock using Mendelian randomization (MR) analysis. The genome-wide association study (GWAS) statistics for epigenetic clocks (HannumAge, intrinsic epigenetic age acceleration [IEAA], PhenoAge, and GrimAge) and sleep traits were obtained from the UK Biobank (UKB), 23andMe and Finngen. Moreover, crucial instrumental variables (IVs) were evaluated. Inverse variance weighted (IVW), MR-Egger, weighted median (WM), weighted mode, and simple mode methods were employed to assess the causal relationship between them. Multiple analyses were performed for quality control evaluation. Our study showed that self-reported insomnia may speed up the aging process by GrimAge clock, while GrimAge acceleration could faintly reduce self-reported insomnia. Epigenetic clocks mainly influence sleep traits by PhenoAge and GrimAge with weak effects. This may indicate that early interventions of SDs could be a breaking point for aging and age-related diseases. Further studies are required to elucidate the potential mechanisms involved.

2 February 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
SLShaohua Lyu
Shaohua Lyu
CZClaire Shuiqing Zhang
Claire Shuiqing Zhang
AZAnthony Lin Zhang
Anthony Lin Zhang
XGXinfeng Guo
Xinfeng Guo
RHRong Hua
Rong Hua
JSJing-Bo Sun
Jing-Bo Sun
Background: Migraine is a prevalent, recurrent condition with substantial disease burden. Chinese herbal medicine (CHM) has been used frequently for migraine in controlled clinical settings. This study is to summarise the characteristics of patients who seek clinical care in a tertiary Chinese medicine hospital in China; to gather their preferences and values of using CHM; to explore the effect of CHM for migraine and its comorbidities in a real-world setting, and to collect first-hand expertise of clinicians’ practice pattern in prescribing CHM for migraine.Methods: This registry-based cohort study was prospectively conducted at Guangdong Provincial Hospital of Chinese Medicine from December 2020 to May 2022. Adult migraine patients seeking their initial anti-migraine clinical care at the hospital were consecutively recruited and followed up for 12 weeks. Practitioners specialised in headache management prescribed individualised treatments without research interference. Standardised case report forms were employed to gather information on patients’ preferences and perspective of seeking clinical care, as well as to assess participants’ migraine severity, comorbidities, and quality of life, at 4-weeks intervals. Various analytical methods were utilised based on the computed data.Results: In this study, we observed 248 participants. Of these, 73 received CHM treatment for 28 days or longer. Notably, these participants exhibited a greater disease severity, compared to those treated with CHM for less than 28 days. Of the 248 participants, 83.47% of them expected CHM would effectively reduce the severity of their migraine, around 50% expected effects for migraine-associated comorbidities, while 51.61% expressing concerns about potential side effects. CHM appeared to be effective in reducing monthly migraine days and pain intensity, improving patients’ quality of life, and potentially reducing comorbid anxiety, with a minimum of 28 days CHM treatment. Herbs such as gan cao, gui zhi, chuan xiong, fu ling, bai zhu, yan hu suo, etc. were frequently prescribed for migraine, based on patients’ specific symptoms.Conclusion: CHM appeared to be beneficial for migraine and comorbid anxiety in real-world clinical practice when used continuously for 28 days or more.Clinical Trial Registration:clinicaltrials.gov, identifier ChiCTR2000041003.